KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
|Recent News||More >>|
KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids
KemPharm Announces Addition to Leadership Team
KemPharm, Inc. Reports First Quarter 2017 Results
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|